SUMMARY, EXPLANATION AND LIMITATIONS:
The c-MYC gene is located at chromosome 8q24. It is required for progression through the cell cycle and promotes cellular proliferation. The t(8;14)(q24;q32) translocation and the c-MYC/immunoglobulin heavy-chain (IGH) fusion gene are not only in Burkitt lymphoma, but are also seen in diffuse large B-cell lymphoma, blastic mantle cell lymphoma and transformed follicular lymphoma. In another study on predicting c-MYC translocation in 17 cases of Burkitt lymphomas (BLs) and 19 cases of diffuse large B-cell lymphomas (DLBCLs), Ruzinova et al. reported that the sensitivity and specificity of this c-Myc antibody on identifying tumor harboring a c-MYC rearrangement reached 96% and 90% respectively. This novel c-Myc antibody is a useful tool for identifying aggressive B-cell lymphomas likely to harbor a c-MYC rearrangement, and thus warrant genetic testing.
Immunogen: A synthetic peptide, aa 408-439, (AEEQKLISEEDLLRKRREQLKHKLEQLRNSCA) from C-terminus of human c-myc.
Staining pattern: Predominantly nuclear with diffuse granular pattern. Cytoplasmic staining was also observed.
Positive control: Tissue sample from breast carcinoma.
This antibody is designed for the specific localization of human c-Myc using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.